SCHEMBL5214248

SCHEMBL5214248

CCC(CC)(c1ccc(NC(=O)CCCCc2sc(-n3cnc4ccccc43)nc2-c2ccc(Cl)cc2)cc1)P(=O)(O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.38
POLB P06746 2/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MGLL Q99685 2/20 0.36
AGER Q15109 1/20 0.35
ALDH1A1 P00352 2/20 0.34
LMNA P02545 2/20 0.34
CASP3 P42574 1/20 0.34
SENP8 Q96LD8 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
SENP6 Q9GZR1 1/20 0.34
HPGD P15428 1/20 0.34
THRB P10828 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
CACNA1G O43497 1/20 0.33
CNR2 P34972 1/20 0.33
KDM4E B2RXH2 1/20 0.33
TNKS O95271 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5208773 0.99 MAPT (0.38) MAPTPOLBMEN1KMT2ASMN1; SMN2
SCHEMBL5211502 0.98 MAPT (0.39) MAPTPOLBMEN1KMT2ASMN1; SMN2
SCHEMBL5209799 0.95 MAPT (0.38) MAPTPOLBMEN1KMT2ASMN1; SMN2
SCHEMBL5213673 0.91 KMT2A (0.47) MAPTPOLBMEN1KMT2ASMN1; SMN2
SCHEMBL5214802 0.89 TNKS (0.37) MAPTPOLBMEN1KMT2ASMN1; SMN2
SCHEMBL5214253 0.84 MGLL (0.38) MAPTPOLBMEN1KMT2ASMN1; SMN2
SCHEMBL5208781 0.83 MGLL (0.38) MAPTPOLBMEN1KMT2ASMN1; SMN2
SCHEMBL5208500 0.82 CNR1 (0.41) MAPTPOLBMEN1KMT2ASMN1; SMN2
SCHEMBL5211510 0.82 MGLL (0.39) MAPTPOLBMEN1KMT2ASMN1; SMN2
SCHEMBL5207013 0.81 MAPT (0.39) MAPTPOLBALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7183276-B2 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-27 US disclosed
US-20050090534-A1 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-28 US disclosed
EP-1486490-A1 AZOLE COMPOUNDS Takeda Chemical Industries, Ltd. (JP) 2004-12-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090534-A1 Azole compounds AHR, NR0B2, NR2C2 MAPT 3958/4885POLB 3507/4885MEN1 1626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.